Clinical Trial Update: Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of defactinib and VS-6766 for metastatic uveal melanoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Defactinib (defactinib)
• VS-6766 (VS-6766)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Metastatic Uveal Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2025-07-15